Autoimmune Diseases

Gilead and Kites exhibit booth at ASH 2025

Gilead's $2.2B Ouro buy delivers TCE, new purpose for Galapagos

Gilead is paying $1.68 billion for a T-cell engager company via a front-loaded deal that could also give new meaning to its aimless partner Galapagos.

James Waldron Mar 24, 2026 3:34am

Sanofi returns to TCEs via $1.2B pact for ph.1-stage trispecific

Mar 23, 2026 9:27am

A ballpoint pen rests on top of a stack of documents ready for signing

UCB enters TCE space with $1.1B deal for autoimmune candidate

Mar 4, 2026 8:20am

Boehringer's $500M pact for oral approach to autoimmune disease

Feb 26, 2026 7:00am

Anatomical model of human arm and torso showing muscle

Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study

Feb 24, 2026 9:15am

Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena

Feb 9, 2026 8:41am